Richards, Merrill & Peterson’s Medifast MED Stock Holding History

Richards, Merrill & Peterson’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4	Closed	-$70	–	516
2024 Q4	$70	Buy	+4	New	+$74	﹤0.01%	501

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Richards, Merrill & Peterson's MED Position: Q1 2025 in Review

Richards, Merrill & Peterson sold out of Medifast (MED) in Q1 2025, closing a stake of 4 shares — an estimated $70 sold.

Richards, Merrill & Peterson first reported a position in MED in Q4 2024 and held it in 1 quarter. The position peaked at $70 in Q4 2024. 124 funds tracked by Wall St. Rank hold MED as of Q1 2025.

Richards, Merrill & Peterson reported no remaining Medifast position as of Q1 2025 after selling out during the quarter.
Richards, Merrill & Peterson sold 4 Medifast shares in Q1 2025, an estimated $70.
Richards, Merrill & Peterson first reported a position in Medifast in Q4 2024 and held it in 1 quarter.
Richards, Merrill & Peterson's Medifast position peaked at $70 in Q4 2024.
124 funds tracked by Wall St. Rank held Medifast as of Q1 2025.

Based on Richards, Merrill & Peterson's 13F filing for Q1 2025, filed 7 May 2025.